Polycystic ovary syndrome: metformin in women not planning pregnancy

References

Bayer plc (2012) Dianette summary of product characteristics [online; accessed 15 January 2013]

British National Formulary (December 2012) [online; accessed 15 January 2013]

Cetinkalp S, Karadeniz M, Erdogan M et al. (2009) The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist 19: 94–7

Cibula D, Fanta M, Vrbikova J et al. (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction 20:180–4

Costello M, Shrestha B, Eden J et al. (2007) Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews issue 1: CD005552

Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction 17: 1729–37

Harborne L, Fleming R, Lyall H et al. (2003) Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 88: 4116–23

Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI et al. (2007) Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 92: 2453–61

Marshall JC, Dunaif A (2012) Should all women with PCOS be treated for insulin resistance? Fertility and Sterility 97:18–22

Medicines and Healthcare products Regulatory Agency (MHRA) (2012) Metformin summary of product characteristics [online; accessed 15 January 2013]

Meyer C, McGrath BP, Teede HJ (2007) Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30: 471–8

Morin-Papunen LC, Vauhkonen I, Koivunen R et al. (2003) Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology & Metabolism 88: 148–56

Morin-Papunen LC, Vauhkonen I, Koivunen RM et al. (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology & Metabolism 85: 3161–8

Wu J, Zhu Y, Jiang Y et al. (2008) Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology 24: 392–8